Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function

NCT00972374 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhegmatogenous Macula-off Retinal Detachment

Interventions

DRUG: 400 ug Brimonidine Implant
DRUG: 200 ug Brimonidine Implant
OTHER: Sham (no implant)

Sponsor

Allergan